Zhang MH, Meng N, Zhang KH, Yu JK, Huang CH, Yang S, Zhu DY. Correlation between gynecomastia and endocrine regulation in patients with metabolic dysfunction-associated fatty liver disease: A cross-sectional study. World J Hepatol 2025; 17(6): 108096 [DOI: 10.4254/wjh.v17.i6.108096]
Corresponding Author of This Article
Ning Meng, PhD, Chief Physician, Professor, Department of Thyroid and Breast Surgery, Affiliated Hospital of Hangzhou Normal University, No. 120 Jinhua Road, Gongchenqiao Street, Gongshu District, Hangzhou 310015, Zhejiang Province, China. mengning0894@126.com
Research Domain of This Article
Medicine, General & Internal
Article-Type of This Article
Observational Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. Jun 27, 2025; 17(6): 108096 Published online Jun 27, 2025. doi: 10.4254/wjh.v17.i6.108096
Correlation between gynecomastia and endocrine regulation in patients with metabolic dysfunction-associated fatty liver disease: A cross-sectional study
Ming-Huang Zhang, Ning Meng, Kang-Hui Zhang, Jun-Kang Yu, Chen-Hao Huang, Shu Yang, Ding-Yi Zhu
Ming-Huang Zhang, Ning Meng, Kang-Hui Zhang, Jun-Kang Yu, Chen-Hao Huang, Shu Yang, Ding-Yi Zhu, Department of Thyroid and Breast Surgery, Affiliated Hospital of Hangzhou Normal University, Hangzhou 310015, Zhejiang Province, China
Author contributions: Zhang MH and Meng N designed the study, analyzed the data and wrote the manuscript; Zhang KH, Yu JK, Huang CH, Yang S and Zhu DY analyzed and collected the data for this study; all authors have read and approved the final manuscript.
Institutional review board statement: This study was approved by the Review Board of Hangzhou Normal University Hospital (No. 2025(E2)-KS-045).
Informed consent statement: The need for patient consent was waived due to the retrospective nature of the study.
Conflict-of-interest statement: All authors declare that there is no conflict of interest.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Data sharing statement: No additional data are available.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ning Meng, PhD, Chief Physician, Professor, Department of Thyroid and Breast Surgery, Affiliated Hospital of Hangzhou Normal University, No. 120 Jinhua Road, Gongchenqiao Street, Gongshu District, Hangzhou 310015, Zhejiang Province, China. mengning0894@126.com
Received: April 7, 2025 Revised: May 6, 2025 Accepted: May 28, 2025 Published online: June 27, 2025 Processing time: 82 Days and 0.3 Hours
Core Tip
Core Tip: This pioneering study investigated the unexplored link between the severity/duration of metabolic dysfunction-associated fatty liver disease (MASLD) and gynecomastia (GYN) in adult males, addressing acritical research gap. By integrating MASLD with body mass index and sex hormone imbalances, we revealed GYN as a novel marker for metabolic disorders (hyperglycemia, hypertension, dyslipidemia), shedding light on MASLD-driven endocrine disruption. Our findings underscore the necessity of holistic metabolic management—targeting obesity, MASLD, and hormonal imbalance—to mitigate GYN progression. This first-of-its-kind analysis provides a transformative clinical framework for early screening and intervention, positioning GYN as a sentinel for underlying metabolic dysfunction, thereby enhancing preventive strategies and therapeutic outcomes for MASLD-related comorbidities.
